Copyright Reports & Markets. All rights reserved.

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Dulaglutide
    • 1.3.3 Exenatide
    • 1.3.4 Liraglutide
    • 1.3.5 Benaglutide
    • 1.3.6 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Diabetes
    • 1.4.3 Obesity
  • 1.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size & Forecast
    • 1.5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020 & 2024 & 2031)
    • 1.5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity (2020-2031)
    • 1.5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (2020-2031)

2 Manufacturers Profiles

  • 2.1 Novo Nordisk
    • 2.1.1 Novo Nordisk Details
    • 2.1.2 Novo Nordisk Major Business
    • 2.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
    • 2.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Novo Nordisk Recent Developments/Updates
  • 2.2 Eli Lilly
    • 2.2.1 Eli Lilly Details
    • 2.2.2 Eli Lilly Major Business
    • 2.2.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
    • 2.2.4 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Eli Lilly Recent Developments/Updates
  • 2.3 AstraZeneca
    • 2.3.1 AstraZeneca Details
    • 2.3.2 AstraZeneca Major Business
    • 2.3.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
    • 2.3.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 AstraZeneca Recent Developments/Updates
  • 2.4 Sanofi
    • 2.4.1 Sanofi Details
    • 2.4.2 Sanofi Major Business
    • 2.4.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
    • 2.4.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Sanofi Recent Developments/Updates
  • 2.5 GSK
    • 2.5.1 GSK Details
    • 2.5.2 GSK Major Business
    • 2.5.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
    • 2.5.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 GSK Recent Developments/Updates
  • 2.6 Hanson
    • 2.6.1 Hanson Details
    • 2.6.2 Hanson Major Business
    • 2.6.3 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
    • 2.6.4 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Hanson Recent Developments/Updates
  • 2.7 Shanghai Benemae
    • 2.7.1 Shanghai Benemae Details
    • 2.7.2 Shanghai Benemae Major Business
    • 2.7.3 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
    • 2.7.4 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Shanghai Benemae Recent Developments/Updates

3 Competitive Environment: Glucagon Like Peptide-1 (GLP-1) Agonists by Manufacturer

  • 3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Manufacturer (2020-2025)
  • 3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturer (2020-2025)
  • 3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Manufacturer (2020-2025)
  • 3.4 Market Share Analysis (2024)
    • 3.4.1 Producer Shipments of Glucagon Like Peptide-1 (GLP-1) Agonists by Manufacturer Revenue ($MM) and Market Share (%): 2024
    • 3.4.2 Top 3 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturer Market Share in 2024
    • 3.4.3 Top 6 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturer Market Share in 2024
  • 3.5 Glucagon Like Peptide-1 (GLP-1) Agonists Market: Overall Company Footprint Analysis
    • 3.5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market: Region Footprint
    • 3.5.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market: Company Product Type Footprint
    • 3.5.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region
    • 4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Region (2020-2031)
    • 4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Region (2020-2031)
    • 4.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Region (2020-2031)
  • 4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020-2031)
  • 4.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020-2031)
  • 4.4 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020-2031)
  • 4.5 South America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020-2031)
  • 4.6 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020-2031)

5 Market Segment by Type

  • 5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
  • 5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Type (2020-2031)
  • 5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Type (2020-2031)

6 Market Segment by Application

  • 6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
  • 6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Application (2020-2031)
  • 6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Application (2020-2031)

7 North America

  • 7.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
  • 7.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
  • 7.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
    • 7.3.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Country (2020-2031)
    • 7.3.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Country (2020-2031)
    • 7.3.3 United States Market Size and Forecast (2020-2031)
    • 7.3.4 Canada Market Size and Forecast (2020-2031)
    • 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

  • 8.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
  • 8.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
  • 8.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
    • 8.3.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Country (2020-2031)
    • 8.3.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Country (2020-2031)
    • 8.3.3 Germany Market Size and Forecast (2020-2031)
    • 8.3.4 France Market Size and Forecast (2020-2031)
    • 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
    • 8.3.6 Russia Market Size and Forecast (2020-2031)
    • 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

  • 9.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
  • 9.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
  • 9.3 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region
    • 9.3.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Region (2020-2031)
    • 9.3.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Region (2020-2031)
    • 9.3.3 China Market Size and Forecast (2020-2031)
    • 9.3.4 Japan Market Size and Forecast (2020-2031)
    • 9.3.5 South Korea Market Size and Forecast (2020-2031)
    • 9.3.6 India Market Size and Forecast (2020-2031)
    • 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
    • 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

  • 10.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
  • 10.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
  • 10.3 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
    • 10.3.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Country (2020-2031)
    • 10.3.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Country (2020-2031)
    • 10.3.3 Brazil Market Size and Forecast (2020-2031)
    • 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

  • 11.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
  • 11.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
  • 11.3 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
    • 11.3.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Country (2020-2031)
    • 11.3.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Country (2020-2031)
    • 11.3.3 Turkey Market Size and Forecast (2020-2031)
    • 11.3.4 Egypt Market Size and Forecast (2020-2031)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
    • 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

  • 12.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
  • 12.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
  • 12.3 Glucagon Like Peptide-1 (GLP-1) Agonists Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Glucagon Like Peptide-1 (GLP-1) Agonists and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Glucagon Like Peptide-1 (GLP-1) Agonists
  • 13.3 Glucagon Like Peptide-1 (GLP-1) Agonists Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Glucagon Like Peptide-1 (GLP-1) Agonists Typical Distributors
  • 14.3 Glucagon Like Peptide-1 (GLP-1) Agonists Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was valued at US$ 111250 million in 2024 and is forecast to a readjusted size of USD 490450 million by 2031 with a CAGR of 23.9% during review period.
    Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
    The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:
    Market Drivers:
    Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.
    Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.
    Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.
    Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.
    Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.
    Market Challenges:
    High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.
    Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.
    Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.
    Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.
    Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.
    Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.
    This report is a detailed and comprehensive analysis for global Glucagon Like Peptide-1 (GLP-1) Agonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
    Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
    Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
    Global Glucagon Like Peptide-1 (GLP-1) Agonists market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Glucagon Like Peptide-1 (GLP-1) Agonists
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Glucagon Like Peptide-1 (GLP-1) Agonists market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Benemae, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Glucagon Like Peptide-1 (GLP-1) Agonists market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Dulaglutide
    Exenatide
    Liraglutide
    Benaglutide
    Other
    Market segment by Application
    Diabetes
    Obesity
    Major players covered
    Novo Nordisk
    Eli Lilly
    AstraZeneca
    Sanofi
    GSK
    Hanson
    Shanghai Benemae
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with price, sales quantity, revenue, and global market share of Glucagon Like Peptide-1 (GLP-1) Agonists from 2020 to 2025.
    Chapter 3, the Glucagon Like Peptide-1 (GLP-1) Agonists competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Glucagon Like Peptide-1 (GLP-1) Agonists breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Glucagon Like Peptide-1 (GLP-1) Agonists.
    Chapter 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, customers, research findings and conclusion.

    Buy now